Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.
J Prev Alzheimers Dis. 2022;9(2):197-210. doi: 10.14283/jpad.2022.30.
J Prev Alzheimers Dis. 2022.
PMID: 35542991
Clinical Trial.